Program

Opening Session: Keynote Presentations

Co-Chairpersons: Tetsuo Noda, JFCR-Cancer Institute, Tokyo, Japan, and Tyler Jacks, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
5:00 p.m.-6:30 p.m.

The cancer epigenome
Peter A. Jones, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Development of therapeutic cancer vaccines and construction of a clinical research network in Japan
Yusuke Nakamura, University of Tokyo Human Genome Center, Tokyo, Japan

Opening Reception

Session 1: Tumor Biomarkers and Diagnostics

Co-Chairpersons: Motoharu Seiki, University of Tokyo, Tokyo, Japan, and Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX, USA
8:00 a.m.-9:30 a.m.

Delivering on the promise of personalized molecular medicine
Gordon B. Mills

Identification of biomarkers and therapy targets by proteomics
Tesshi Yamada, National Cancer Center Research Institute, Tokyo, Japan

Targeting ErbB3 in ErbB2-expressing breast cancers
Rebecca S. Cook, Vanderbilt University, Nashville, TN

Session 2: Pharmacogenomics

Co-Chairpersons: Yusuke Nakamura, University of Tokyo, Tokyo, Japan, and Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA
10:00 a.m.-11:30 a.m.

Pharmacogenomics-based individualization of anticancer therapeutics
Taisei Mushiroda, RIKEN, Tokyo, Japan

Molecular characterization of circulating tumor cells
Daniel A. Haber

Pharmacogenetics of irinotecan in Japanese patients with cancer
Hironobu Minami, Kobe University Graduate School of Medicine, Kobe, Japan

Session 3: New Approaches to Cancer Immunotherapy

Co-Chairpersons: Louis M. Weiner, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA, and Masanori Hatakeyama, Hokkaido University, Sapporo, Japan
11:30 a.m.-1:00 p.m.

Monoclonal antibody immunotherapy
Louis M. Weiner

Improvement of immunotherapy by restoration of immunocompetence through targeting signaling molecules in cancer and immune cells
Yutaka Kawakami, Keio University, Tokyo, Japan

Immune correlates of clinical outcomes in dendritic cells vaccination
A. Karolina Palucka, Baylor University Medical Center, Dallas, TX, USA

Poster Session A

Session 4: Drug Delivery Systems for Cancer Therapy

Co-Chairpersons: Kohei Miyazono, University of Tokyo, Tokyo, Japan, and Sara A. Courtneidge, Burnham Institute for Medical Research, La Jolla, CA, USA
8:00 p.m.-9:30 p.m.

Individualized therapeutics through the rational design of multistage nanovectors
Mauro Ferrari, UT Health Science Center, Houston, TX, USA

Polymeric micellar drugs and gene vectors for cancer treatment
Kazunori Kataoka, University of Tokyo School of Engineering, Tokyo, Japan

Targeting tumors using viral nanoparticles (VNPs)
Marianne Manchester, The Scripps Research Institute, La Jolla, CA, USA

Session 5: Stem Cells and Cancer

Co-Chairpersons: Catriona H. M. Jamieson, UCSD Moores Cancer Center, La Jolla, CA, USA, and Masaki Mori, Osaka University, Beppu, Japan
8:00 a.m.-9:30 a.m.

Niche regulation for cancer stem cells
Toshio Suda, Keio University School of Medicine, Tokyo, Japan

Title not provided
Richard A. Young, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Regulation of hematopoietic stem cell homeostasis and leukemia
Atsushi Hirao, Kanazawa University Cancer Research Institute, Kanazawa, Japan

Session 6: Cancer Genomics

Co-Chairpersons: Yoshio Miki, Tokyo Medical and Dental University, Tokyo, Japan, and Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA
10:00 a.m.-11:30 a.m.

Genome-wide expression analysis identified MRG-binding protein (MRGBP) as a gene involved in colorectal carcinogenesis
Yoichi Furukawa, University of Tokyo, Institute of Medical Science, Tokyo, Japan

Genomic alterations in human cancers
Matthew L. Meyerson

A genome-wide association study for non-small cell lung cancer susceptibility in the Korean population
Kyong-Ah Yoon, National Cancer Center, Goyang-si, Republic of Korea

Poster Session B

Session 7: Epidemiology and Cancer Prevention

Co-Chairpersons: Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, TX, USA, and Kazuo Tajima, Aichi Cancer Center, Nagoya, Japan
8:00 p.m.-9:30 p.m.

Genetic traits for H. pylori persistent infection, atrophic gastritis, and gastric carcinogenesis
Nobuyuki Hamajima, Nagoya University Graduate School of Medicine, Nagoya, Japan

The molecular prevention-therapy convergence
Scott M. Lippman

Metabolic factors and the risk of cancer: Data from a large-scale population-based cohort study in Japan (JPHC Study)
Manami Inoue, National Cancer Center, Tokyo, Japan

Session 8: Cancer Epigenomics

Co-Chairpersons: Peter A. Jones, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA, and Fuyuki Ishikawa, Kyoto University, Kyoto, Japan
8:00 a.m.-9:30 a.m.

Regulation of the cancer epigenome
Peggy J. Farnham, University of California, Davis, CA, USA

DNA methylation profiles in precancerous conditions and cancers: Carcinogenetic risk estimation and prognostication based on DNA methylation status
Yae Kanai, National Cancer Center Research Institute, Tokyo, Japan

Decoding the human epigenome
Bing Ren, Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA

Session 9: Non-coding RNAs in Cancer

Co-Chairpersons: Hitoshi Nakagama, National Cancer Center, Tokyo, Japan, and Carlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
10:00 a.m.-11:30 a.m.

Causes and consequences of microRNA dysregulation in cancer
Carlo M. Croce

MicroRNA alterations in human lung cancers
Takashi Takahashi, Nagoya University Graduate School of Medicine, Nagoya, Japan

Noncoding RNAs for medical practice
George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX, USA

Poster Session C

Session 10: Tumor Microenvironment

Co-Chairpersons: Hiroyasu Esumi, National Cancer Center, East Hospital, Kashiwa, Japan, and Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA
8:00 p.m.-9:30 p.m.

TGF-β signaling in tumor microenvironment
Kohei Miyazono, University of Tokyo Graduate School of Medicine, Tokyo, Japan

Regulation of in situ to invasive breast carcinoma progression
Kornelia Polyak

Development of an antibody therapy against synovial sarcoma targeting a novel antigen identified through analysis of a genome-wide gene expression profile
Chikako Fukukawa, University of Tokyo Institute of Medical Science, Tokyo, Japan

Session 11: Tumor Microenvironment (continued)

8:00 a.m.-9:30 a.m.

Reprogramming the epigenome in carcinogenesis
Thea D. Tlsty, University of California School of Medicine, San Francisco, CA, USA

Original and biological functions of cancer stromal fibroblasts
Atsushi Ochiai, National Cancer Center, Hospital East, Kashiwa, Japan

Tumor-associated macrophages at the cutting edge of cancer invasion
Johanna A. Joyce, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Session 12: Novel Therapeutics

Co-Chairpersons: Geoffrey M. Wahl, Salk Institute Cancer Center, La Jolla, CA, USA, and Morito Monden, Osaka University, Suita, Japan
10:00 a.m.-11:30 a.m.

HB-EGF is a novel therapeutic target for ovarian cancer: Development of an HB-EGF inhibitor as an anticancer drug
Eisuke Mekada, Osaka University, Suita, Japan

Title not provided
Yu Chen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Regulation and functions of the Akt/PKB pathway
Yukiko Gotoh, University of Tokyo, Tokyo, Japan

Poster Session D

Session 13: Novel Therapeutics (continued)

5:00 p.m.-6:30 p.m.

Development of novel cancer therapeutics
William N. Hait, Ortho Biotech Oncology Research and Development Johnson & Johnson, Raritan, NJ, USA

CCR4 as a novel specific molecular target for immunotherapy in ATL
Ryuzo Ueda, Nagoya City University, Nagoya, Japan

Genetic predictors of RAF/MEK-dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Closing Reception and Dinner

Departure